Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Evidence for EMF-Cancer Link Deemed Weak, Risk Small

August 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

RESEARCH TRIANGLE PARK, NC-After 6 years of research and 2 years of review, the National Institute of Environmental Health Sciences reported to Congress that the evidence that low-frequency electromagnetic fields (EMFs) can cause cancer and other human diseases is weak, but added that EMF exposure “cannot be recognized as entirely safe.”

RESEARCH TRIANGLE PARK, NC—After 6 years of research and 2 years of review, the National Institute of Environmental Health Sciences reported to Congress that the evidence that low-frequency electromagnetic fields (EMFs) can cause cancer and other human diseases is weak, but added that EMF exposure “cannot be recognized as entirely safe.”

A 1996 report by the Institute of Medicine found scant evidence to support EMF as a cancer risk, and federal investigators recently discredited a study from the Energy Department’s Lawrence Berkeley Laboratory because a scientist omitted data that did not support a link between EMFs and cancer.

Articles in this issue

False positives frequent in CT lung cancer screening trial
Stereotactic Core Biopsy Establishes Many Prognostic Factors
Breast Cancer Prevention With Tamoxifen Appears Cost-Effective
NCI Discovers Gene Variations From Existing Databases
CPDR Unveils First Center Solely for Prostate Cancer Research
Going Beyond CHOP in Advanced Large-Cell Lymphoma
Memorial Sloan-Kettering Opens Rockefeller Outpatient Pavilion
Ernst Wynder, Pioneer in Preventive Medicine
AHCPR Plans Health Care Market, Managed Care Research Centers
NSAIDs May Protect Against Common GI Cancers
Four Researchers Receive General Motors Awards
Anal Condylomata More Threatening in HIV+ Patients
IOM Finds No Link Between Silicone Implants and Cancer
IL-12 Gene Therapy Inhibits Osteosarcoma Lung Mets in Mice
Law May Play an Important Role in End of Life Decisions

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.

Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer

Russ Conroy
June 10th 2025
Article

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.

Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC

Russ Conroy
June 10th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

FDA Lifts Hold on IFx-2.0 in Advanced/Metastatic Merkel Cell Carcinoma

Roman Fabbricatore
June 9th 2025
Article

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.


Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer

Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer

Tim Cortese
June 9th 2025
Article

Satri-cel led to a median PFS of 3.25 months vs 1.77 months with physician’s choice in patients with pretreated gastric or gastroesophageal cancer.

Related Content

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.

Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer

Russ Conroy
June 10th 2025
Article

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.

Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC

Russ Conroy
June 10th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

FDA Lifts Hold on IFx-2.0 in Advanced/Metastatic Merkel Cell Carcinoma

Roman Fabbricatore
June 9th 2025
Article

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.


Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer

Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer

Tim Cortese
June 9th 2025
Article

Satri-cel led to a median PFS of 3.25 months vs 1.77 months with physician’s choice in patients with pretreated gastric or gastroesophageal cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.